BioRestorative Therapies (BRTX) Stock Price, News & Analysis

Company Overview

BioRestorative Therapies, Inc. (OTCMKTS:BRTX) is a clinical-stage biotechnology company dedicated to developing regenerative medicine therapies for urological, orthopedic and rehabilitative indications. The company’s research focuses on autologous and allogeneic cell therapy platforms designed to repair, regenerate and restore normal tissue function through targeted cell delivery and expansion technologies.

Among its lead programs is BRTX-100, an investigational autologous muscle cell therapy aimed at treating stress urinary incontinence, which is advancing through late-stage clinical studies. The company is also developing BRTX-200, a muscle-derived cell therapy for male erectile dysfunction, along with early-stage programs targeting tendon and ligament injuries. These therapies employ minimally invasive cell harvesting and processing methods to reduce immune risk and enhance patient outcomes.

Headquartered in Culver City, California, BioRestorative Therapies collaborates with clinical research centers and regulatory agencies across the United States to conduct its trials. Its scientific team brings together expertise in cell biology, tissue engineering and clinical development, guiding the translation of laboratory discoveries into potential commercial treatments. The company is committed to addressing unmet medical needs by harnessing the body’s own healing capabilities.

Key Stats

• Today's Range: $1.57 to $1.63
• 50-Day Range: $1.43 to $1.84
• 52-Week Range: $1.19 to $2.55
• Volume: 16,063 shs
• Average Volume: 180,553 shs
• Market Capitalization: $12.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed this year?

BioRestorative Therapies' stock was trading at $1.43 at the beginning of the year. Since then, BRTX shares have increased by 10.1% and is now trading at $1.5750.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies's stock reverse split before market open on Wednesday, October 27th 2021.The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioRestorative Therapies investors own include Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), Onconova Therapeutics (ONTX) and American Graphite Technologies (AGIN).

Company Calendar

• Today: 10/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Healthcare
• Current Symbol: OTCMKTS:BRTX
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: (631) 760-8100
• Fax: N/A
• Employees: 7
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): ($1.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.50 million
• Net Margins: -13,728.83%
• Pretax Margin: -13,728.83%
• Return on Equity: -120.47%
• Return on Assets: -114.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.81
• Quick Ratio: 14.81

Sales & Book Value

• Annual Sales: $605.20 thousand
• Price / Sales: 20.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.65 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 7,978,000
• Free Float: 3,660,000
• Market Cap: $12.57 million
• Optionable: Not Optionable
• Beta: -0.69